间充质干细胞治疗新型冠状病毒肺炎的研究进展与应用前景

Mesenchymal stem cells in therapy of coronavirus disease 2019 — a review

摘要:

当前新型冠状病毒肺炎疾病已在全球大规模蔓延，严重危害人类的健康。新病毒感染性强并且感染后重症患者病死率较高，目前尚无有效的特异性治疗药物，因此亟待寻找安全有效的治疗方法。间充质干细胞 (Mesenchymal stem cells，MSCs) 具有强大的免疫调节和组织损伤修复与再生的生物学功能，因此作为一种干细胞疗法有潜力降低新冠肺炎重症患者的组织损伤和死亡率。目前，我国和国外多家研究机构已启动多项MSCs治疗新型冠状病毒肺炎的相关临床研究项目，已初步证实该疗法的安全性和有效性，因此具有非常良好的临床治疗前景。

Abstract:

Coronavirus disease 2019 (COVID-19) has spread widely on a large scale in the whole world at present, seriously endangering human health. There are still no effective and specific drugs, so it is urgent to find safe and effective therapeutic methods. Mesenchymal stem cells (MSCs) have many biological functions of powerful immunomodulation and tissue repair and regeneration. As a stem cell therapy, it has the potential to reduce the tissue injury and mortality in severe patients infected with novel coronavirus. At present, many research institutions in China and abroad have started a number of clinical research projects about MSCs in the treatment of COVID-19. In addition, those projects have initially confirmed the safety and effectiveness of this therapy. Therefore, this research field has been proved to have a very good clinical therapy prospect.